… between apixaban and other direct oral anticoagulants (DOACs) are available. Few real-world
studies comparing the effectiveness and safety between DOACs have been conducted. …

Background Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are at
least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among …

… Based on an analysis of data from the Dresden registry and the registry of the Department of
Defense … At 30 days of follow-up, 18% of the patients in the safety population experienced a …

… characteristics of our study population. The majority of the study population were female (…
The data that support the findings of this study are available from the United States Defense …

… have demonstrated that direct oral anticoagulants (DOACs) are … Using US Department of
Defense (DOD) data, this study … Conclusion: Among NVAF patients in the US DOD population, …

… an imbalance between oxidative stress and antioxidant defense. All these factors may play
… treatment, for the very elderly patients, are the same of the general population and included …

… also its potential in pediatric populations, marking it as a pivotal option in the evolving landscape
of … Interestingly, PAR4 appears to contribute to host defense by enhancing the systemic …

… Despite the large burden of vascular risk factors in the NH population, we observed ischemic
stroke rates generally consistent with anticoagulants in BAFTA and the DOAC trials. Rates …

… risk for thrombosis in a population that may already be at … anticoagulant activity (97).
Furthermore there may be assay-dependency of INR values in LA patients on oral anticoagulation. …

… or dabigatran by utilizing United States Department of Defense administrative claims.[32] It
… with the expanding aging population. As we initiate patients on oral anticoagulant therapy it …